Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Sanofi reports Q2 2024 Dupixent® (Dupilumab) Sales Over €3.3B

Jul 25, 2024

On 25 July 2024, Sanofi revealed that its worldwide sales of Dupixent (dupilumab) grew by 29.2% to €3,303 million in the second quarter of 2024.  Sanofi expects the product to generate revenue of about €13 billion for 2024. 

Earlier this month, Dupixent® received European approval as an add-on maintenance treatment for adults with uncontrolled COPD, the first approval of Dupixent for COPD anywhere in the world.  In May 2024, the FDA accepted Sanofi’s and Regeneron’s sBLA for Dupixent® for adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).